NxStage Medical (NXTM) Upgraded to Sell at BidaskClub
NxStage Medical (NASDAQ:NXTM) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.
NXTM has been the topic of several other research reports. Zacks Investment Research upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Canaccord Genuity restated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research note on Tuesday, October 17th. Northland Securities restated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research note on Wednesday, November 8th. Finally, ValuEngine downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Friday. Two investment analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. NxStage Medical has an average rating of “Hold” and a consensus price target of $30.25.
Shares of NxStage Medical (NASDAQ:NXTM) traded down $0.23 during trading on Monday, hitting $24.86. 1,025,565 shares of the stock traded hands, compared to its average volume of 499,499. The firm has a market capitalization of $1,661.77, a P/E ratio of -355.14 and a beta of -0.08. NxStage Medical has a twelve month low of $20.45 and a twelve month high of $30.80.
Institutional investors and hedge funds have recently bought and sold shares of the business. Public Employees Retirement Association of Colorado acquired a new stake in NxStage Medical during the fourth quarter worth $128,000. Prudential Financial Inc. acquired a new stake in NxStage Medical during the third quarter worth $202,000. Amalgamated Bank boosted its stake in NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after buying an additional 553 shares in the last quarter. Athos Capital Ltd acquired a new stake in NxStage Medical during the third quarter worth $557,000. Finally, Suntrust Banks Inc. boosted its stake in NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after buying an additional 209 shares in the last quarter. Hedge funds and other institutional investors own 85.56% of the company’s stock.
WARNING: “NxStage Medical (NXTM) Upgraded to Sell at BidaskClub” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/02/06/nxstage-medical-nxtm-upgraded-to-sell-at-bidaskclub.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.